Most of what gets cited about apigenin online traces back to cell and animal research. That is not a criticism of the compound, it is simply the current state of the science, and it is important context before deciding whether to try it. This article focuses specifically on what human research exists, and is honest about how thin that body of evidence still is.
Disclosure: ApigeninHub is a participant in the Amazon Services LLC Associates Program. Some links in this article are affiliate links, and we may earn a commission on qualifying purchases at no extra cost to you.
Why Human Data Is Limited
Apigenin is a naturally occurring compound found in common foods, which means it has not gone through the same commercial drug-development pipeline that produces large randomized controlled trials. Most funding for apigenin research has come from academic and preclinical cancer-biology labs, not from companies running Phase 2 or Phase 3 human trials.
As a result, the strongest apigenin evidence sits at the cell-culture and animal-model level, with a much smaller number of human studies, many of them small, short, or focused on chamomile extract rather than isolated apigenin.
Why Placebo Control Matters Here
Sleep and anxiety are notoriously susceptible to placebo response. Expectation is measurable rather than hypothetical: in an open-label chamomile extract trial for generalized anxiety disorder, patients who expected more benefit at baseline were more likely to respond (odds ratio 1.69, p = 0.002), and patients who expected more side effects reported more side effects [5]. Any apigenin study, or any chamomile study, needs a placebo arm to distinguish a real effect from expectation and natural symptom fluctuation.
Research note: In coronary syndrome patients, two nights of inhaling chamomile essential oil lowered anxiety, blood pressure and heart rate versus sesame oil placebo (P < 0.001). This is an essential oil, not apigenin [12].
Chamomile Extract Human Studies
Because chamomile is the most common dietary source of apigenin, several human trials have studied chamomile extract for anxiety and sleep, and these are the closest thing to human apigenin data available. The anxiety side is the stronger of the two, and it is still thin. One 8-week randomized, double-blind, placebo-controlled trial in 57 adults with mild to moderate generalized anxiety disorder found a significantly greater reduction in Hamilton Anxiety scores on chamomile than on placebo, though the margin was slim (P = 0.047) and the authors asked for replication[1]. A later, larger trial tested whether staying on chamomile prevented relapse over 26 weeks and missed its primary endpoint: relapse was numerically less frequent on chamomile but not significantly so (hazard ratio 0.52, 95% CI 0.20 to 1.33, P = 0.16), even though symptom scores stayed lower[2].
Sleep is where the honest answer changes direction. The one randomized, double-blind, placebo-controlled trial of chamomile for chronic primary insomnia, in 34 adults taking 270 mg twice daily for 28 days, found no significant difference from placebo on any sleep diary measure, and total sleep time actually favored the placebo group[3]. That is worth knowing before buying anything marketed for sleep on the strength of chamomile’s reputation.
It is important to note that chamomile extract contains dozens of compounds beyond apigenin, so these results cannot be attributed to apigenin alone. They are the closest human data, but results are mixed: the anxiety trial was borderline, the relapse trial missed its primary endpoint, and the insomnia trial was null [1][2][6].
What Isolated Apigenin Human Trials Exist
Controlled human trials on isolated, standardized apigenin supplements (as opposed to chamomile extract) remain scarce. Two human studies of pure apigenin exist in the evidence: a study in healthy men that measured how apigenin is absorbed and excreted from three different sources (pure apigenin, chamomile tea and a parsley drink), rather than whether it treats anything, and a 4-week trial of 1% apigenin cream in 40 adults [4][7]. Sample sizes at that scale are typical here, and results should be treated as preliminary rather than conclusive.
One 2026 trial did test a blend containing 50 mg of apigenin (with magnesium L-threonate and L-theanine) in 103 healthy adults. The evening arm had 25 people and did not produce significant improvements, so apigenin alone remains untested for sleep [11].
This gap is the single most important thing to understand about apigenin’s evidence base: the mechanistic story (GABA-A binding, CD38 inhibition, antioxidant activity) rests on lab work that is partly conflicting, since apigenin alone inhibited GABA activation in cells and CD38 inhibition was shown at test-tube concentrations, [8][9][10] but the leap to “this many milligrams produces this effect in a general adult population” has not been rigorously tested the way it has for many pharmaceutical compounds.
Cancer Research Context
Apigenin’s most extensive research base is actually in preclinical oncology, where it has been studied for effects on various cancer cell lines and animal tumor models. This research is scientifically interesting and is part of why apigenin is taken seriously in flavonoid research circles, but it is preclinical. No human clinical trial has established apigenin supplementation as a cancer treatment or prevention strategy, and it should never be treated as a substitute for medical care.
How to Read Apigenin Research Responsibly
When you see a headline like “apigenin fights cancer” or “apigenin cures anxiety,” it is worth asking three questions: was this a cell study, an animal study, or a human study; what dose was used relative to what a supplement actually delivers; and was there a placebo control. Applying those three filters clears up most of the overstated claims that circulate about this compound.
A Comparison of Evidence Strength by Claim
| Claim area | Strongest evidence type available |
|---|---|
| Calming/anxiety effect | One positive placebo-controlled chamomile trial (P = 0.047), plus one relapse-prevention trial that missed its primary endpoint; limited isolated-apigenin human data |
| Sleep support | Mechanistic (GABA-A, with conflicting cell results); the one placebo-controlled chamomile insomnia trial found no significant benefit over placebo, and an evening blend with 50 mg apigenin did not significantly change sleep disturbance in 103 adults [8][6][11] |
| Cancer-related mechanisms | Extensive cell and animal research; no human treatment trials |
| NAD+/CD38 pathway | Cell and animal research only |
| Skin/UV protection | Cell and animal research; one 4-week human trial of 1% apigenin cream in 40 adults measured cosmetic skin outcomes [7] |
Frequently Asked Questions
Has apigenin been tested in a large human clinical trial?
Not in the way pharmaceutical drugs typically are. Most apigenin-specific evidence comes from cell and animal research, with a smaller number of small human studies, largely on chamomile extract rather than isolated apigenin.
Is it safe to try apigenin while waiting for more human research?
Apigenin from food sources like chamomile tea has a long history of use. Supplement doses are higher than typical dietary intake, so talk to a healthcare provider first, especially if you take prescription medication.
Why do so many articles cite the same handful of studies?
Because the isolated-apigenin human research base is genuinely small. When you see the same study referenced repeatedly across different articles, it usually means that study represents a meaningful fraction of the available human data on that specific question.
Will more human trials happen?
Interest in flavonoids and NAD+ metabolism has grown in recent years, which may drive more funding toward human apigenin research, but no large trials are publicly known to be underway as of this writing.
References
- Amsterdam JD et al. A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. J Clin Psychopharmacol (2009). PMID 19593179
- Mao JJ et al. Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial. Phytomedicine (2016). PMID 27912875
- Zick SM et al. Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: a randomized placebo-controlled pilot study. BMC Complement Altern Med (2011). PMID 21939549
- Borges G et al. Absorption, distribution, metabolism and excretion of apigenin and its glycosides in healthy male adults. Free Radic Biol Med (2022). PMID 35452808
- Keefe JR et al. Specific expectancies are associated with symptomatic outcomes and side effect burden in a trial of chamomile extract for generalized anxiety disorder. J Psychiatr Res (2017). PMID 27716513
- Atena Pasban et al. The Effect of Chamomile on Common Psychological Disorders Including Depression, Anxiety, Stress and Sleep Disorders: A Narrative Review. Iranian Journal of Psychiatry and Behavioral Sciences (2025). doi:10.5812/ijpbs-157547
- Choi S et al. Apigenin inhibits UVA-induced cytotoxicity in vitro and prevents signs of skin aging in vivo. International journal of molecular medicine (2016). PMID 27279007
- Campbell EL et al. The dietary flavonoids apigenin and (-)-epigallocatechin gallate enhance the positive modulation by diazepam of the activation by GABA of recombinant GABA(A) receptors. Biochemical pharmacology (2004). PMID 15451406
- Goutman JD et al. Flavonoid modulation of ionic currents mediated by GABA(A) and GABA(C) receptors. European journal of pharmacology (2003). PMID 12586201
- Carlos Escande et al. Flavonoid Apigenin Is an Inhibitor of the NAD+ase CD38. Diabetes (2012). PMID 23172919
- Mastrofini GF et al. Modulating stress and sleep through a multi-compound dietary supplement: a randomized, double-blind, placebo-controlled trial. Journal of the International Society of Sports Nutrition (2026). PMID 42829807
- Pourshaikhian M et al. Effects of aromatherapy with Matricaria chamomile essential oil on anxiety and hemodynamic indices in patients with acute coronary syndrome, 2021: a randomized controlled trial. BMC complementary medicine and therapies (2024). PMID 38172912
These statements have not been evaluated by the FDA. Apigenin is not intended to diagnose, treat, cure, or prevent any disease. Talk to a qualified healthcare provider before starting any new supplement, especially if you take prescription medication.
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
